Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanassios Argiris

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Head & Neck|March 5, 2026
Different Pattern of Treatment Failure After Chemoradiation Between p16+ and p16- Patients Affected by Oropharyngeal CarcinomaRiccardo Gili, Paolo Bossi, Luca Lalli, et al.
Cancer Medicine|June 7, 2024
Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinomaAngela E Alnemri, Sruti Tekumalla, Annie E Moroco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancerAthanassios Argiris, Dwight E Heron, Ryan P Smith, et al.
Frontiers in Oncology|December 21, 2020
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment EffectDante J Merlino, Jennifer M Johnson, Madalina Tuluc, et al.
Molecular Oncology|October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle studyChul S Ha, Joel E Michalek, Richard Elledge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303Ann Marie Egloff, Ju-Whei Lee, Corey J Langer, et al.
Cancer|September 21, 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neckAntonio Jimeno, Marshall R Posner, Lori J Wirth, et al.
Cancer|May 5, 2017
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancerAhmad A Tarhini, Imran Rafique, Theofanis Floros, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2022
Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 TrialXu Liu, Ling Guo, Fang-Yun Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancerAthanassios Argiris, Austin G Duffy, Shivaani Kummar, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Head & Neck|March 5, 2026
Different Pattern of Treatment Failure After Chemoradiation Between p16+ and p16- Patients Affected by Oropharyngeal CarcinomaRiccardo Gili, Paolo Bossi, Luca Lalli, et al.
Cancer Medicine|June 7, 2024
Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinomaAngela E Alnemri, Sruti Tekumalla, Annie E Moroco, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2010
Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancerAthanassios Argiris, Dwight E Heron, Ryan P Smith, et al.
Frontiers in Oncology|December 21, 2020
Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment EffectDante J Merlino, Jennifer M Johnson, Madalina Tuluc, et al.
Molecular Oncology|October 7, 2015
p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle studyChul S Ha, Joel E Michalek, Richard Elledge, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 10, 2014
Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303Ann Marie Egloff, Ju-Whei Lee, Corey J Langer, et al.
Cancer|September 21, 2016
A phase 2 study of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neckAntonio Jimeno, Marshall R Posner, Lori J Wirth, et al.
Cancer|May 5, 2017
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancerAhmad A Tarhini, Imran Rafique, Theofanis Floros, et al.
International Journal of Radiation Oncology, Biology, Physics|May 13, 2022
Adjuvant Apatinib in Nasopharyngeal Carcinoma With Residual Epstein-Barr Virus DNA After Radiation Therapy: A Biomarker-Driven, Phase 2 TrialXu Liu, Ling Guo, Fang-Yun Xie, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2011
Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancerAthanassios Argiris, Austin G Duffy, Shivaani Kummar, et al.
Pageof 13